Table 2.
Clinical trials registered at ClinicalTrials.gov on stem cell therapy for COPD.
| Registry code | Trial status | Patient (n) | Cell/drug type | Cell source | Mode of administration | Schedule of administration | Dosage of administration | Other special treatment | Primary outcome measures | Follow-up period |
| NCT02348060 | Recruiting | 100 | AD-SVF | Autologous | i.v. | Single dose | – | – | Quality of life | 1 year |
| NCT04047810 | Recruiting | 15 | MSCs | – | i.v. | Single dose | (0.5–2) × 106/kg | – | Number of adverse events | 1 year |
| NCT03040674 | Recruiting | 200 | BM-MCs | Autologous | i.v. | Single dose | – | – | Quality of life and FEV1 | 1 year |
| NCT03909750 | Recruiting | 50 | AD-SVF | Autologous | i.v. | Single dose | – | – | Safety and pulmonary function | 6 months |
| NCT02946658 | Recruiting | 100 | AD-SVF | Autologous | i.v. | Single dose | – | – | Safety and pulmonary function | 1 year |
| NCT04206007 | Active, not recruiting | 9 | UC-MSCs | Allogeneic | i.v. | Single dose | – | – | Number of adverse events | 1 year |
| NCT04018729 | Not yet recruiting | 34 | BM-MSCs | Autologous | i.t. | Single dose | – | Endobronchial valve | Number of adverse events and quality of life | 6 months |
| NCT02216630 | Completed | 26 | AD-SVF | Autologous | i.v. | Single dose | – | – | FEV1 and number of adverse events | 1 year |
| NCT02645305 | Completed | 20 | AD-SVF | Autologous | i.v. | Single dose | – | Platelet rich plasma | Blood SGOT levels | 1 year |
| NCT01758055 | Unknown | 12 | BM-MSCs | Unknown | i.v. | Single dose | 0.6 × 108 | – | Pulmonary function | 1 year |
| NCT02135380 | Unknown | 60 | AD-SVF | Autologous | i.v. | 3 times, once a week | 2 × 106/kg | – | Safety | 1 year |
| NCT03044431 | Unknown | 214 | BM-MCs | Autologous | i.v. | Single dose | – | Platelet rich plasma | FEV1 and quality of life | 6 months |
| NCT02412332 | Unknown | 20 | BM-MSCs/AD-MSCs | Autologous | i.v. | Single dose | 1 × 108 | – | Pulmonary function | 1 year |
| NCT01849159 | Withdrawn | - | BM-MSCs | Allogeneic | i.v. | 6 times, once 2 months | – | – | Safety | 2 years |
| NCT03228121 | Withdrawn | - | BM-MCs | Autologous | i.v. | 3 times, once a day | – | Platelet rich plasma | Quality of life and FEV1 | 1 year |
| NCT01559051 | Terminated | - | AD-SVF | Autologous | i.v. | Single dose | – | – | Number of adverse events and 6-min walk test | 6 months |
| NCT02161744 | Terminated | 9 | AD-SVF | Autologous | i.v. | Single dose | – | – | Safety | 1 year |
AD-MSCs: Adipose-derived mesenchymal stem cells; AD-SVF: Adipose-derived stromal vascular fraction; BM-MCs: Bone marrow-derived mesenchymal cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; CAT: COPD assessment test; COPD: Chronic pulmonary obstructive disease; FEV1: Forced expiratory volume in the first second; i.v.: Intravenous injection; i.t.: Intratracheal injection; MSCs: Mesenchymal stem cells; SGOT: Serum glutamic-oxaloacetic transaminase; UC-MSCs: Umbilical cord-derived mesenchymal stem cells.